ADGM

Adagio Medical Holdings, Inc Common Stock
ADGM
Market cap $37.5M

2.80 USD

-0.08

2.78%

At close Oct 18, 4:00 PM EDT

1 day

-2.78%

5 days

-2.10%

1 month

-34.27%

3 months

-69.06%

6 months

-69.06%

Year to date

-69.06%

1 year

-69.06%

5 years

-69.06%

About: Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.

Healthcare Surgical & Medical Instruments & Apparatus

–

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ADGM.

See Analyst Rankings

Financial journalist opinion

Adagio Medical Announces Participation in the 19th Annual International Symposium on Ventricular Arrhythmias

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced its sponsorship and participation in the 19th Annual International Symposium on Ventricular Arrhythmias, to be held at the New York Marriott at the Brooklyn Bridge on October 11-12, 2024. In addition to participating in the commercial exhibition, Adagio's proprietary Ultra-Low Temperature C.

Adagio Medical Announces Participation in the 19th Annual International Symposium on Ventricular Arrhythmias

Adagio Medical Provides Business Updates

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at.

Adagio Medical Provides Business Updates

See News Rankings

Charts implemented using Lightweight Charts™